- Home
- DIBS vs SGMT Comparison
DIBS vs SGMT Comparison
Compare DIBS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DIBS | SGMT |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 169.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DIBS | SGMT |
|---|---|---|
| Price | $4.68 | $7.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $26.13 |
| AVG Volume (30 Days) | 326.9K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,620,000.00 | $2,000,000.00 |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.54 | N/A |
| 52 Week Low | $2.50 | $4.50 |
| 52 Week High | $6.62 | $11.41 |
Technical Indicators
Market Signals| Indicator | DIBS | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 54.97 |
| Support Level | $3.75 | $7.09 |
| Resistance Level | $4.83 | $7.95 |
| Average True Range (ATR) | 0.37 | 0.45 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 38.26 | 57.48 |
Price Performance
Historical ComparisonAbout DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.